Table 3.
Variables | Echocardiographic responder | Echocardiographic nonresponder | p valuea | Functional responder | Functional nonresponder | p valuea |
---|---|---|---|---|---|---|
Demographics | ||||||
Age, years | 64.5 (33; 88) | 67.5 (33; 88) | 0.43 | 65 (35; 85) | 66 (33; 88) | 0.66 |
Male | 89/116 (76.7) | 52/58 (89.7) | 0.04 | 76/97 (78.4) | 80/97 (82.5) | 0.47 |
BMI | 28.98 ± 5.56 | 29.68 ± 5.52 | 0.44 | 29.43 ± 5.62 | 28.41 ± 6.27 | 1.00 |
Medical history | ||||||
DCMP | 66/116 (56.9) | 24/58 (41.4) | 0.05 | 56/97 (57.7) | 42/97 (43.3) | 0.04 |
ICMP | 50/116 (43.1) | 37/58 (63.8) | 0.01 | 44/97 (45.4) | 56/97 (57.7) | 0.09 |
Laboratory values | ||||||
NT-proBNP pg/ml | 452 (13; 4203) | 1097 (159; 4571) | 0.003 | 544.5 (13; 4571) | 457 (152; 4331) | 0.75 |
NYHA classification | ||||||
III | 19/69 (27.5) | 13/35 (37.1) | 0.08 | 10/64 (15.6) | 25/44 (56.8) | <0.001 |
IV | 1/69 (1.4) | 2/35 (5.7) | 0.08 | 0/64 (0.0) | 3/44 (6.8) | <0.001 |
Echocardiographic values | ||||||
LVEF, % | 38 (15; 64) | 22.5 (13; 55) | < 0.001 | 33 (15; 60) | 37 (13; 64) | 0.11 |
TAPSE, mm | 19.5 (2.5; 31) | 17 (11; 27) | 0.01 | 19 (11; 31) | 18 (2.5; 31) | 0.34 |
Clinical outcomes | ||||||
Mortality | 6/116 (5.2) | 7/58 (12.1) | 0.1 | 3/97 (3.1) | 11/97 (11.3) | 0.01 |
Congestion | 5/70 (4.3) | 7/35 (20.0) | 0.05 | 6/65 (9.2) | 5/45 (11.1) | 0.75 |
Hospitalization | 40/74 (54.1) | 21/38 (55.3) | 0.97 | 38/67 (56.7) | 23/52 (44.2) | 0.18 |
Data are presented as n (%), median (minimum; maximum), or mean ± standard deviation unless otherwise indicated
Bold text indicates a statistically significant difference with a p-value less than 0.05
BMI body mass index, DCMP dilated cardiomyopathy, ICMP ischemic cardiomyopathy, LVEF left ventricular ejection fraction, NT-proBNP N-terminal pro-B-type natriuretic peptide, NYHA New York Heart Association, TAPSE tricuspid annular plane systolic excursion
ap values for the comparison between responders and nonresponders